High Blood Pressure & Cardiovascular Prevention最新文献

{"title":"Association Between Naples Prognostic Score and All-Cause Mortality in Individuals with Cardio-Renal-Metabolic Multimorbidity: A Cohort Study.","authors":"Song Wen, Wei Shi, Xingjie Huang, Zhexuan Deng, Hua Yang, Nan Chen, Lingbing Meng","doi":"10.1007/s40292-026-00803-7","DOIUrl":"10.1007/s40292-026-00803-7","url":null,"abstract":"<p><strong>Introduction: </strong>The Naples Prognostic Score (NPS) has demonstrated prognostic value in oncology and certain chronic diseases. Its utility in cardio-renal-metabolic multimorbidity (CRMM) remains unexplored.</p><p><strong>Aim: </strong>This study aims to evaluate the association between NPS and all-cause mortality in individuals with CRMM.</p><p><strong>Methods: </strong>We analyzed data from the National Health and Nutrition Examination Survey (1999-2018) comprising 3,602 adults with CRMM. The NPS was derived from serum albumin, total cholesterol (TC), neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR). Weighted Cox proportional hazards models and restricted cubic spline (RCS) analysis were used to evaluate associations between NPS and all-cause mortality.</p><p><strong>Results: </strong>Over a median follow-up of 79 months, 1,621 (41.4%) deaths occurred. After comprehensive adjustment for potential confounders, each 1-point increase in NPS was associated with a 24.6% higher risk of all-cause mortality (HR 1.246, 95% CI 1.150-1.350, P < 0.0001). The HRs for all-cause mortality was 1.133 (95 % CI: 0.846-1.518, P = 0.401) in the medium NPS group and 1.721 (95 % CI: 1.248-2.375, P = 0.0009) in the high NPS group, as compared with the low NPS group. RCS analysis indicated a nonlinear relationship between NPS and all-cause mortality among participants with CRMM (Pnonlinear=0.014). Weighted quantile sum regression analysis identified NLR as the primary contributor to mortality risk (weight: 0.612 at 2 years, 0.580 at 5 years), followed by TC.</p><p><strong>Conclusion: </strong>This study identified a positive, nonlinear association between NPS and all-cause mortality in CRMM individuals. The NPS integrates inflammatory, metabolic, and nutritional biomarkers into a practical prognostic tool that may enhance risk stratification and guide personalized management in multimorbidity.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"557-568"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex Differences in the Usefulness of Unattended Blood Pressure Measurement in Patients with Arterial Hypertension.","authors":"Ilaria Fucile, Maria Virginia Manzi, Maria Lembo, Maddalena Tesone, Alessandro Maloberti, Valeria Bisogni, Christian Basile, Grazia Canciello, Lucia La Mura, Martino F Pengo, Giulio Geraci, Fabio Bertacchini, Silvia Monticone, Valeria Visco, Giacomo Pucci, Costantino Mancusi","doi":"10.1007/s40292-026-00795-4","DOIUrl":"10.1007/s40292-026-00795-4","url":null,"abstract":"<p><strong>Introduction: </strong>Unattended blood pressure (BP) measurement was introduced following the results of the SPRINT study. Conflicting results have been reported in relation to the concordance between unattended BP, attended BP and 24-hour ambulatory monitoring (ABPM).</p><p><strong>Aim: </strong>To evaluate the concordance between measurements of BP in unattended, attended and ABPM modes, and to analyse sex differences in the diagnostic accuracy in relation to the 24h ABPM.</p><p><strong>Methods: </strong>307 patients were enrolled in 6 hypertension centers belonging to the Italian Society of Hypertension. Patients underwent BP measurement in unattended and attended modes before ABPM. BP was defined as controlled if the 24-hour average blood pressure was <130/80 mmHg on ABPM.</p><p><strong>Results: </strong>Patients with 59.6 ±13.6 years, with a female prevalence of 48% and a duration of hypertensive disease of 11.6±8.4 years were enrolled. The unattended and attended BP values were 136±16/ 78 ±11 mmHg and 137±19/ 82±13 mmHg respectively (p<0.05 for diastolic BP). In ROC curve analysis, the unattended BP showed an accuracy in correctly identifying patients with uncontrolled hypertension equal to 0.71, higher than attended BP, equal to 0.65 (p<0.05). This difference in a sex-specific analysis was larger for females in whom the unattended BP measurement showed an AUC of 0.712 versus an AUC of 0.620 for the attended BP (p<0.05).</p><p><strong>Conclusions: </strong>Our data suggests that unattended BP may be particularly useful in identifying patients with uncontrolled BP more accurately than attended BP. This advantage, due to a virtual elimination of the white coat effect, is more marked in females.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"527-534"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thoracoscopic Sympathectomy in Treatment-Resistant Essential Hypertension: A Novel Approach to Reduce Sympathetic Activity and Blood Pressure.","authors":"Mark Reinhard, Amal Derai, Niels Henrik Buus, Per Løgstrup Poulsen, Morten Bendixen, Peter Juhl-Olsen, Kent Lodberg Christensen","doi":"10.1007/s40292-026-00792-7","DOIUrl":"10.1007/s40292-026-00792-7","url":null,"abstract":"","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"605-613"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Symptoms of Anxiety and Depression and Blood Pressure Variability in Older Outpatients.","authors":"Roberto Presta, Giulia Rivasi, Alice Ceccofiglio, Sara Rogani, Laura Orlandi, Ludovica Ceolin, Luigi Scavino, Alessandro Mengozzi, Enrico Brunetti, Chiara Mussi, Agostino Virdis, Andrea Ungar, Mario Bo","doi":"10.1007/s40292-026-00797-2","DOIUrl":"10.1007/s40292-026-00797-2","url":null,"abstract":"<p><strong>Introduction: </strong>Blood pressure variability (BPV) predicts cardiovascular risk beyond average BP, but evidence on the role of anxiety/depression on BPV in older adults is limited.</p><p><strong>Aim: </strong>To evaluate the association of anxiety and depressive symptoms with short-term BPV and white-coat effect (WCE) in older outpatients undergoing ambulatory blood pressure monitoring (ABPM).</p><p><strong>Methods: </strong>Cross-sectional multicenter study of outpatients aged ≥ 65 years undergoing 24-h ABPM across Italian geriatric centers. Anxiety and depressive symptoms were assessed with GAD-7, STAI-Y1/Y2 and GDS-15. Short-term BPV was quantified by daytime systolic average real variability (ARV). The office-daytime BP difference was calculated (ΔSBP and ΔDBP), and WCE was defined categorically as ΔSBP ≥ 20 mmHg and/or ΔDBP ≥ 10 mmHg. Multivariable models were adjusted for clinical and pharmacological confounders.</p><p><strong>Results: </strong>Among 235 outpatients (median age 76.4 years, 60.0% female), anxiety prevalence varied widely by scale (GAD-7: 34.9%; STAI-Y1: 74.0%; STAI-Y2: 73.2%), while depressive symptoms were present in 28.5%. ARV did not significantly differ in patients screening positive or negative for anxiety (GAD-7: 16.4 vs 15.5 mmHg, p = 0.349; STAI-Y1: 16.2 vs 14.9 mmHg, p = 0.214; STAI-Y2: 16.2 vs 14.8 mmHg, p = 0.160), or between those with and without depressive symptoms (15.9 vs 15.8 mmHg, p = 0.902); also, after adjustment for potential confounders. WCE prevalence was 40.9% and was higher in participants screening negative for depressive symptoms (39.2% vs 23.9%, p = 0.039). ΔSBP tended to be higher in participants screening negative for anxiety (GAD-7: 7.6 vs 3.3 mmHg, p = 0.095) and depressive symptoms (GDS-15: 7.6 vs 2.6 mmHg, p = 0.065).</p><p><strong>Conclusions: </strong>Anxiety and depressive symptoms were not independently associated with short-term BPV in older outpatients. WCE/ΔSBP were generally higher, albeit non significantly, in participants without anxiety or depression. These findings suggest that psychological symptoms may contribute only modestly to short-term BP fluctuations in older adults.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"535-546"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147836717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Cardiovascular Risk Modeling of Orforglipron Using the PREVENT Equations Compared with the Pooled Cohort Equations: A Post-Hoc Analysis from a Systematic Review and Meta-analysis.","authors":"Adir Alper, Adina Fagin, Aditya Karthikeyan, Avrohom Karp, Rika Terashima, Hamsa Murli, Adam Gershon, Robert Faillace","doi":"10.1007/s40292-026-00814-4","DOIUrl":"10.1007/s40292-026-00814-4","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Orforglipron, an oral non-peptide GLP-1 receptor agonist, improves multiple cardiometabolic risk factors. However, prior modeling used only the 2013 Pooled Cohort Equations (PCE), which ignore body mass index (BMI), estimated glomerular filtration rate (eGFR), and hemoglobin A1c (HbA1c). We re-evaluated its cardiovascular benefit using the 2023 AHA PREVENT equations, which account for more nuanced variables.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To compare the projected cardiovascular risk reduction from orforglipron when modeled using the 2013 PCE versus the 2023 AHA PREVENT equations, and to quantify the additional exploratory cardiometabolic benefit captured by PREVENT's equations.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;In this post-hoc analysis, we applied pooled effect estimates from our systematic review and meta-analysis of five orforglipron RCTs to representative hypothetical patient profiles. We calculated 10-year and 30-year Cardiovascular disease (CVD) risk using the 2013 PCE and the 2023 PREVENT equations (base and HbA1c-enhanced models) at baseline and after modeled treatment effects at each dose (12, 24, 36, and 45 mg). Absolute and relative risk reductions were compared across tools. A sensitivity analysis was performed using the 95% confidence interval of the pooled treatment effects.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In these modeled scenarios, the PREVENT HbA1c-enhanced model projected model-dependent relative risk reductions approximately 75-90% larger than those generated by the PCE across all patient profiles and dose tiers. For a representative 50-year-old man with T2D BMI 33 kg/m², HbA1c 8.0%, SBP 130 mmHg, TC 200 mg/dL, HDL 42 mg/dL, eGFR 85 mL/min/1.73 m²), the PCE estimated a 10-year RRR of 16.8% at the 36 mg dose, whereas PREVENT HbA1c-enhanced projected an RRR of 31.4% at the same dose-driven by additional capture of BMI reduction (- 2.6 kg/m²), HbA1c lowering (- 1.40%). Approximately one-third of the projected total risk reduction by PREVENT was attributable to HbA1c alone, a dimension the PCE structurally cannot assess. PREVENT also projected a 22.4% reduction in 10-year heart failure risk, a dimension absent from the PCE. PREVENT yielded lower baseline risk estimates than the PCE, consistent with known PCE overestimation. Notably, the PREVENT ASCVD-specific model projected reclassification of Profile A from borderline to low risk (&lt; 5.0%) at all doses, whereas the PCE showed no reclassification from intermediate risk at any dose.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The AHA PREVENT equations may more comprehensively capture the projected cardiovascular benefit of orforglipron than the legacy PCE. In these modeled scenarios, exclusive reliance on the PCE may provide a less complete estimate of the projected cardiometabolic risk-factor benefit of orforglipron. For therapies targeting the cardiovascular-kidney-metabolic axis, PREVENT may offer a more comprehensive and clinically informative framework for ","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"517-526"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotype-Guided Renal Denervation: the Key to Therapeutic Response.","authors":"Ehsan Shahverdi, Lars Roman Herda, Sendooran Shahi, Mathias Lange, Carsten Schneider","doi":"10.1007/s40292-026-00809-1","DOIUrl":"10.1007/s40292-026-00809-1","url":null,"abstract":"<p><p>Renal denervation (RDN) has re-entered the therapeutic landscape of hypertension following contemporary sham-controlled trials demonstrating reproducible reductions in blood pressure. However, variability in treatment response remains a defining feature, raising important questions regarding its clinical applicability. Emerging evidence indicates that this heterogeneity is primarily attributable to differences in patient phenotype rather than limitations of device technology. This narrative review synthesizes evidence from randomized trials, meta-analyses, and key observational studies to examine determinants of response to RDN across clinical and mechanistic domains. Particular emphasis is placed on hypertension phenotype, ambulatory blood pressure characteristics, baseline blood pressure levels, medication adherence, sympathetic nervous system activity, renal artery anatomy, and associated comorbid conditions. Available data consistently suggest that patients with sustained hypertension confirmed by ambulatory monitoring, higher baseline blood pressure, and features indicative of sympathetic overactivity derive greater benefit from denervation. In contrast, pseudoresistance, white-coat hypertension, advanced vascular stiffness, and unfavorable anatomical characteristics are associated with attenuated or inconsistent responses. Reinterpretation of contemporary trial data further indicates that the magnitude of blood pressure reduction, although moderate, is clinically meaningful when applied to appropriately selected populations. These findings support a shift toward mechanism-based, phenotype-guided patient selection as a means to reconcile prior inconsistencies, optimize clinical implementation, and inform future research. Within this framework, RDN may be more appropriately positioned as a targeted adjunctive therapy in personalized hypertension management.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"487-502"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Luis E Simental-Mendía, Laura Jazel Barragán-Zúñiga, Valeria Reyes-Avitia","doi":"10.1007/s40292-026-00812-6","DOIUrl":"10.1007/s40292-026-00812-6","url":null,"abstract":"<p><strong>Introduction: </strong>It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile. However, the impact of triple agonist retatrutide on these metabolic markers remains to be elucidated.</p><p><strong>Aim: </strong>This meta-analysis aims to investigate the effect of retatrutide on blood pressure and lipid levels through a meta-analysis of randomized controlled trials.</p><p><strong>Methods: </strong>The search process was performed in PubMed, Cochrane Library, Scopus, and ClinicalTrials.gov databases using MeSH terms and keywords. For meta-analysis, a random-effects model and the generic inverse variance method were used.</p><p><strong>Results: </strong>The meta-analysis showed that retatrutide significantly decreases systolic blood pressure (WMD: - 6.79 mmHg, 95% CI: - 8.36, - 5.23, p < 0.0001, I²= 20%) and diastolic blood pressure (WMD: - 2.46 mmHg, 95% CI: - 3.25, - 1.67, p < 0.0001, I²= 0%). Furthermore, a significant reduction in the levels of total cholesterol (WMD: - 21.88 mg/dL, 95% CI: - 27.79, - 15.97, p < 0.0001, I²= 84%), LDL-C (WMD: - 13.10 mg/dL, 95% CI: - 16.10, - 10.10, p < 0.0001, I²= 47%), and triglycerides (WMD: - 40.90 mg/dL, 95% CI: - 48.50, - 33.30, p < 0.0001, I²= 53%) was observed after retatrutide treatment. However, this triple hormone receptor agonist had no significant effect on HDL-C concentrations (WMD: - 0.01 mg/dL, 95% CI: - 1.30, 1.27, p = 0.98, I²= 0%).</p><p><strong>Conclusions: </strong>The results of our meta-analysis revealed that retatrutide treatment decreases blood pressure and improves lipid profile by reducing total cholesterol, LDL-C, and triglyceride levels.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"503-516"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and Projections for Aortic Stenosis and Hypertension-Related Mortality Among Older Adults in the United States: A Retrospective Population-Based Analysis.","authors":"Muhammad Imaz Bhatti, Muhammad Safiullah, Kanza Farhan, Noor Ul Ain Saleem, Omar Abdullah Gill, Muhammad Talha, Muhammad Nabeel Saddique, Atif Hussain Sarwar, Richard A Krasuski","doi":"10.1007/s40292-026-00800-w","DOIUrl":"10.1007/s40292-026-00800-w","url":null,"abstract":"<p><strong>Introduction: </strong>Aortic stenosis (AS) and hypertension (HTN) frequently co-exist in older adults, worsening disease progression and increasing mortality risk compared to either condition alone.</p><p><strong>Aim: </strong>To examine mortality trends and demographic-geographic disparities from comorbid AS and HTN in the U.S. from 1999-2020.</p><p><strong>Methods: </strong>Data were extracted from the CDC WONDER Multiple Cause of Death database. Crude and age-adjusted mortality rates (CMRs, AAMRs) per 100,000 were calculated. Joinpoint regression estimated annual (APC) and average annual percent change (AAPC). Trends were projected to 2030 using an autoregressive integrated moving average (ARIMA) model.</p><p><strong>Results: </strong>Between 1999 and 2020, 100,507 deaths were attributed to comorbid AS and HTN. The overall AAMR significantly increased (AAPC: 5.01%), with a steep rise from 1999-2001 (APC: 21.95%) and consistent increase from 2001-2020 (APC: 3.46%). AAMRs were higher in men (11.6) than women (10.1). NH Whites had the highest AAMR (11.4), followed by Hispanic/Latino and NH Black (7.4), and NH Asian/Pacific Islanders (6.2). AAMRs also varied by region (West: 13.5; Midwest: 11.5; Northeast: 10.7; South: 8.6). Most deaths occurred in medical facilities (34.4%) or at home (31.5%). Vermont, Minnesota, New Hampshire, California, and Nebraska had the highest AAMRs. Non-metropolitan areas had higher AAMRs than metropolitan (11.4 vs. 10.6). Adults ≥ 85 years had the highest CMR (53.6). ARIMA projected AAMR to reach 25.4 by 2030 (22.0 in females, 28.3 in males).</p><p><strong>Conclusion: </strong>Mortality from concurrent AS and HTN is rising, with notable demographic and geographic disparities. Early detection, integrated care, and targeted public health strategies are critical.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"569-581"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atherogenic Index of Plasma as Predictor for Cardiovascular Events and Cardiometabolic Diseases:Findings from the PAMELA Study.","authors":"Alessandro Maloberti, Rita Facchetti, Ana Jelakovic, Cesare Cuspidi, Guido Grassi","doi":"10.1007/s40292-026-00807-3","DOIUrl":"10.1007/s40292-026-00807-3","url":null,"abstract":"<p><strong>Introduction: </strong>The Atherogenic Index of Plasma (AIP), ratio between triglycerides and high-density lipoprotein cholesterol, has been associated with cardiovascular (CV) events, metabolic syndrome and hypertension (HT)-related vascular organ damage. However, the majority of the published studies suffer from important limitations, such as the cross-sectional or retrospective nature and the performance in selected Asian populations only.</p><p><strong>Aim: </strong>We performed a data analysis in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study, examining longitudinally the relationships between AIP, diabetes mellitus (DM), HT and left ventricular hypertrophy (LVH) in a western European general population.</p><p><strong>Methods: </strong>At the study entry baseline data were collected in 2035 subjects, while longitudinal data were obtained in 1412 subjects examined for a median follow-up time lasting 10.7 years.</p><p><strong>Results: </strong>50.6% of the subjects were males, aged 50.9 ± 13.7 (mean ± SD) yrs. During the follow-up AIP did not significantly change (from - 0.11 ± 0.3 to - 0.12 ± 0.29 a.u., P = NS), while systolic BP and plasma glucose significantly increased, with a significant relationship with HT, DM and LVH development (P < 0.0001). At multivariable analysis, AIP significantly and independently predicted the above-mentioned outcomes, with the exception of HT development based on home BP. The same significant association was detected for fatal and non-fatal CV events.</p><p><strong>Conclusions: </strong>These data provide evidence that in a general European population characterized by a low CV risk AIP significantly and independently predicts HT, DM and LVH development and is significantly associated with the composite outcome of CV morbidity and mortality.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":"593-603"},"PeriodicalIF":2.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148143408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Dietary Inflammatory Index and Dietary Oxidative Balance Score with Mortality Among Individuals with Cardiovascular-Kidney-Metabolic Syndrome.","authors":"Xiaohua Wang, Hewanmeng Geng, Zihang Yue, Jiaqi Zhang, Siyu Liu, Chengxiang Hu, Zhirong Li, Yue He, Yanan Ma, Lina Jin","doi":"10.1007/s40292-026-00820-6","DOIUrl":"https://doi.org/10.1007/s40292-026-00820-6","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiovascular-kidney-metabolic (CKM) syndrome represents a complex interplay of cardiovascular, kidney, and metabolic disorders. Dietary factors, particularly those with pro-inflammatory and pro-oxidant properties, may influence disease progression and mortality, yet their role in the CKM syndrome population remains underexplored.</p><p><strong>Aim: </strong>To evaluate potential associations of the dietary inflammatory index (DII), the dietary oxidative balance score (DOBS), and mortality in individuals with CKM syndrome.</p><p><strong>Methods: </strong>A total of 17,317 individuals with CKM syndrome were enrolled and stratified into three groups: stage 0, stages 1-3, and stage 4. DII and DOBS were derived from 26 and 16 preselected dietary components, respectively. Kaplan-Meier analysis, Cox proportional-hazards models, and forest plots were used to examine the associations between dietary scores and mortality across CKM stages.</p><p><strong>Results: </strong>No significant associations were found in stage 0. In stages 1-3 and 4, pro-inflammatory/pro-oxidant diets were associated with increased mortality, with HRs for all-cause, cardiovascular, and non-cardiovascular mortality of 1.46 (1.10-1.94), 1.42 (0.70-2.87), and 1.47 (1.09-1.98) in stages 1-3, and 2.07 (1.33-3.20), 2.20 (1.06-4.59), and 2.01 (1.25-3.24) in stage 4, respectively.</p><p><strong>Conclusions: </strong>Pro-inflammatory and pro-oxidant dietary patterns, as measured by DII and DOBS, are associated with an increased risk of all-cause and non-cardiovascular mortality in both CKM stages 1-3 and stage 4, and with cardiovascular mortality specifically in stage 4. No significant association with cardiovascular mortality was observed in stages 1-3.</p>","PeriodicalId":12890,"journal":{"name":"High Blood Pressure & Cardiovascular Prevention","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}